PET Tracer Kinetic Modelling

SINAPSE ASM Edinburgh 16th June 2010

Vin Cunningham Aberdeen Biomedical Imaging Centre School of Medical Sciences University of Aberdeen



Radiopharmaceuticals

Carbon-11

[11C]Flumazenil

[11C]Ro 15-4513

[11C]SCH 23390

[11C]Raclopride

[11C]FLB 457

[11C]RTI-32

[11C]Diprenorphine

R-[11C]PK 11195

[carbonyl-11C]WAY-100635

[11C]MDL 100907

m-[11C]Hydroxyephedrine

S-[11C]CGP 12177

[11C]GB 67

2-[11C]Thymidine

Radioligand receptor target/type of radiotracer

Central Benzodiazepine

Central Benzodiazepine

Dopamine D1

Dopamine D2

Dopamine D2

Dopamine transporter site

Opiate

PK binding site

Serotonergic 5-HT1A Serotonergic 5-HT2A

Noradrenaline uptake site

b-Adrenergic


a1-Adrenoceptors

Cell proliferation


Occupancy

- Occupancy studies measure occupancy of the target by the candidate drug.
- Require the existence or development of a PET ligand (usually different from the candidate drug).
- Occupancy studies best performed just after or during FTIH


Occupancy of 5HT2A receptors by risperidone using [11C]MDL100907




MRI



Binding Potential Maps (mL/g)
Baseline Scan After 4 mg risperidone



The standard neuroreceptor ligand model



Mintun, M.A. et al., A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography, Ann. Neurol. 15 (1984) 217–227.


The situation in vivo is more complex


Usually only one or two compartments are identifiable and these do not necessarily correspond to the neat partitions suggested by the model

The Individual microparameters are often not numerically identifiable.

Even when they are, their apparent values do not 'behave' as would be expected from the Classic model. Eg PGP effects and 'k4 = koff'

Does this matter?







Non-displaceable with free fraction = f_p

Non-displaceable with free fraction = f_{ND}


Reference Regions





Occupancy of NK1 receptor sites by an exogenously administered antagonist.



Translational Medicine and Technology







Baseline H3 PET (0-90mins)

4hr post **50 ug** GSK189254A (0-90mins)

Structural MRI

Plasma Input Models

Reversible Kinetics

$$IRF(t) = \sum_{i=1}^{n} \phi_i e^{-\theta_i t}$$

$$V_D = \int_0^\infty IRF(t) dt = \sum_{i=1}^n \frac{\phi_i}{\theta_i}$$

Irreversible Kinetics

$$IRF(t) = \sum_{i=1}^{n-1} \phi_i e^{-\theta_i t} + \phi_n$$


$$K_I = \lim_{t \to \infty} IRF(t) = \phi_n$$

n = Number of Tissue Compartments(Nearly all these models have positive coefficients)

$$\theta_i > 0, \quad K_1 = \sum_{i=1}^n \phi_i$$


Occupancy Plot in absence of true reference region

$$(V T_{baseline} - V T_{blocked}) = Occ.V T_{baseline} - Occ.VND$$





Occupancy = 91.0 ± 3.3%

Measurement of Occupancy - Previously











Measurement of Occupancy - Current







PK/PD Models

Model I: C_p-K_d Model

 Assumes the free brain concentration is equal to the plasma concentration and that the occupancy is instantaneously related in a E-Max way to the brain concentration

$$TOC(t) = \frac{C_P(t)}{C_P(t) + K_d}$$


Model II: BBB Limited Model

 Assumes brain concentration is described as a single exponential convolved with the plasma concentration and that the occupancy is instantaneously related in a EMax fashion to the brain concentration.

$$TOC(t) = \frac{C_P(t) \otimes e^{-\beta t}}{C_P(t) \otimes e^{-\beta t} + \gamma}$$

Model III: k_{on}-k_{off} Limited Model

Assumes receptor association and dissociation are finite.



GSK206136 5-HTT 11C-DASB Subject 204

